Mobile

A clinical trial to see if the combination CC-486 plus fulvestrant is effective and safe, compared to fulvestrant alone, in patients with metastatic breast cancer that is estrogen receptor-positive an...

Update Il y a 4 ans
Reference: EUCTR2014-003220-52

A clinical trial to see if the combination CC-486 plus fulvestrant is effective and safe, compared to fulvestrant alone, in patients with metastatic breast cancer that is estrogen receptor-positive and human epidermal growth factor receptor 2-negative

Woman Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

To evaluate the efficacy of CC-486 in combination with fulvestrant relative to fulvestrant monotherapy, by estimation of the hazard ratio of progression free survival (PFS)

Inclusion criteria

  • Postmenopausal female subjects with estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) metastatic breast cancer, who have progressed on an aromatase inhibitor (AI)

Links